Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00477_DB01624_nanopub.RAUBIQtmY30f7kbh4eo7dtNU0Y7FjPEdZJJWurvb9oJLg#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00477_DB01624 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00477_DB01624 label "DDI between Chlorpromazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed. [drugbank_resource:DB00477_DB01624]" assertion.
- drugbank_resource:DB00477_DB01624 identifier "drugbank_resource:DB00477_DB01624" assertion.
- drugbank_resource:DB00477_DB01624 title "DDI between Chlorpromazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed." assertion.
- drugbank:DB01624 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00477_DB01624 assertion.
- drugbank:DB00477 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00477_DB01624 assertion.